About IPM Chirana
IPM Group has partnered with Chirana Medical, one of the leaders of medical innovations in Central and Eastern Europe, to scale up the production of Chirana’s proprietary ICU lung ventilator Aura V among the growing COVID-19 demands levels worldwide.
Chirana Medical is a Slovak based company, founded in 1935, focusing on the production of medical and dental devices. Since its conception, Chirana has been an innovative leader of Central and Eastern Europe, manufacturing the first “artificial heart” that originated from Eastern Europe in 1959 as well as a world-renowned defibrillator, receiving a Grand Prix in Brussels in 1958. Chirana's long tradition of producing breathing apparatus dates back to 1968 - since then, almost 80 000 pieces of breathing and anesthetic devices were produced. Chirana's unique Aura V is one of the best ventilation systems in the world, assisting in the treatment of pneumonia, H1N1, and acute respiratory distress syndrome (“ARDS”) patients. Aura V is also specifically designed to assist the patients with COVID-19 outbreak and challenges arising from its rapid spread.
Features unique to the Aura V ventilator include programmed multilevel ventilation (PMLV), AI driven adjustments, wireless operation possibilities, automated operation, etc.
Chirana’s current production is increasing to produce around 1,200 ventilators yearly - marking a historical moment by producing first Chirana ventilators in the US. Chirana and IPM Group have also entered into a strategic partnership with top US consultants and manufacturers who are working together on U.S. FDA approval and global scaling of manufacturing to a capacity of over 5,000 units per year. IPM Chirana represents IPM Group’s first partnership in medical technology, further supporting IPM’s InfraTech strategy focused on long-term innovative technologies.
